- European indices under downward pressure
- DAX tries to stay in the zone of yesterday's closes
- Deutsche Bank analysts boost sentiment around Symrise
Overall market situation:
Tuesday's session on European stock indices brings moderate declines. The German DAX is doing ‘relatively’ well, staying in the zone of yesterday's closes. The situation is much worse for the French CAC40, which loses 0.64%, the British FTSE 100 (-0.3%) and the Polish WIG20, which loses 0.93%. Today's session once again does not bring an excessive amount of published macro data. Investors' attention will turn to individual companies and statements by Fed bankers. The CB confidence reading from the US may also be important.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
European companies traded lower during Tuesday's trading session. Source: xStation 5
Volatility currently observed in the DAX index. Source: Bloomberg Financial LP
The German benchmark DE40 is recording minimal declines during today's session. The benchmark continues to hold within the structure of the downtrend initiated on 16 May (it was breached yesterday, however). In the medium term, the continuation of the downtrend may create room to test the historically important support level in the zone of the 50-day exponential moving average (blue curve on the chart). Locally, the most important resistance all the time remains the historical peak at 19,000 points and the local barrier defined by the former historical peak of 2 April this year (zone of 18840 points, tested now). Source: xStation 5
News:
Deutsche Bank raises its recommendation on Symrise (SY1.DE) to ‘buy’ from ‘hold’, citing improved earnings momentum. Furthermore, Deutsche highlights positive volume leverage and cost cuts.
Based on higher margin assumptions, the bank is raising EPS expectations for FY24-26 by 4-6%. The company's shares are currently gaining 2.5%.
Symrise share chart, D1 interval. Source: xStation
This morning, we saw slight declines on Fresenius (FRE.DE) shares. The shares of the dialysis subsidiary FMC lost up to two per cent in the MDax after the Economic Times report on the research success of Chinese scientists in the fight against diabetes. Diabetes can cause kidney damage as a secondary disease. Successes in treating diabetes could therefore slow down the dialysis business.
Other news coming from individual companies of the DAX index. Source: Bloomberg Financial LP
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
